Literature DB >> 15466972

A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus.

Tammy S Shields1, Louise A Brinton, Robert D Burk, Sophia S Wang, Stephanie J Weinstein, Regina G Ziegler, Yevgeniy Y Studentsov, Mary McAdams, Mark Schiffman.   

Abstract

Oncogenic human papillomavirus (HPV) infections, the necessary cause of most cervical cancers, are common and usually clear within 1 to 2 years. Identifying cofactors that lead to cancer among HPV-infected women has depended mainly on case-control studies defining HPV by DNA testing. DNA testing assesses only current infection; thus, concerns about residual confounding remain. To assess cofactors, we used seropositivity to five oncogenic HPV types as a marker of past exposure and confined our analysis to seropositive controls compared with cancer cases. Study subjects had participated in a multicenter U.S. case-control study conducted in the early 1980s. The detailed questionnaire and stored sera for 235 cases of squamous carcinoma and 486 controls motivated the reanalysis. We measured antibodies to HPV types 16, 18, 31, 45, and 52. Independent, significant predictors of seropositivity among controls included numbers of sexual partners, Black race, and oral contraceptive use. Condom use was protective. Among HPV-exposed women, Papanicolaou screening, Black race, and yeast infection were significantly associated with reduced cancer risk. Current smoking was associated with a 2-fold increase in risk; there were independent, significant trends of increased risk with numbers of cigarettes smoked (P for trend = 0.003) and years of smoking (P for trend = 0.01). Other significant predictors of increased risk included low education and income and history of nonspecific genital infection. Unlike recent HPV DNA-based investigations, based on the use of HPV-seropositive controls in this study, oral contraceptive use was unrelated to the risk of cervical cancer and multiparity was only weakly related to risk. It is particularly worth considering further why studies of different designs are inconsistent regarding the effect of oral contraceptive use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466972

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  25 in total

1.  Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use.

Authors:  C S Furniss; M D McClean; J F Smith; J Bryan; K M Applebaum; H H Nelson; M R Posner; K T Kelsey
Journal:  Ann Oncol       Date:  2008-12-15       Impact factor: 32.976

Review 2.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

3.  Human papillomaviruses as therapeutic targets in human cancer.

Authors:  Karin Hellner; Karl Münger
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Recent intrauterine device use and the risk of precancerous cervical lesions and cervical cancer.

Authors:  Sarah Averbach; Michael J Silverberg; Wendy Leyden; Karen Smith-McCune; Tina Raine-Bennett; George F Sawaya
Journal:  Contraception       Date:  2018-04-17       Impact factor: 3.375

5.  Multifactorial etiology of cervical cancer: a hypothesis.

Authors:  Harry W Haverkos
Journal:  MedGenMed       Date:  2005-11-30

6.  Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic.

Authors:  Petroula Stamataki; Athanasia Papazafiropoulou; Ioannis Elefsiniotis; Margarita Giannakopoulou; Hero Brokalaki; Eleni Apostolopoulou; Pavlos Sarafis; George Saroglou
Journal:  BMC Infect Dis       Date:  2010-02-15       Impact factor: 3.090

7.  Orbital metastasis of keratinizing squamous cell cervical carcinoma with giant cells. A case report.

Authors:  Jeffrey M Gosslee; Raghunath P Misra; Marlyn P Langford; Bryan Vekovius; William A Byrd; Steven B Flynn
Journal:  Int Ophthalmol       Date:  2007-11-02       Impact factor: 2.031

8.  Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.

Authors:  Dianne J Marais; Debbie Constant; Bruce Allan; Henri Carrara; Margaret Hoffman; Samuel Shapiro; Chelsea Morroni; Anna-Lise Williamson
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

9.  Risks for cervical intraepithelial neoplasia 3 among adolescents and young women with abnormal cytology.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Charles Wibbelsman; Adaleen Powers; Teresa M Darragh; Sepideh Farhat; Ruth Shaber; Stephen Shiboski
Journal:  Obstet Gynecol       Date:  2008-12       Impact factor: 7.661

Review 10.  Human papillomavirus and cervical cancer.

Authors:  Kehinde Sharafadeen Okunade
Journal:  J Obstet Gynaecol       Date:  2019-09-10       Impact factor: 1.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.